BioSpace News Archive

Immutep Limited today announces two abstracts have been selected for poster presentation at the upcoming 2023 American Society of Clinical Oncology’s (ASCO) Annual Meeting, taking place in-person and online from 2-6 June 2023 in Chicago, Illinois (United States).

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of clinical abstracts for multiple programs across its precision therapy portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to 6.

Covalon Technologies Ltd., an advanced medical technologies company, announced its attendance at the 48th Annual Canadian Vascular Access Association Conference and World Congress on Vascular Access Special Event from Wednesday, April 26 to Friday, April 28, 2023 in Toronto, Canada.

Innate Pharma SA announced that it has filed a prospectus supplement with the Securities and Exchange Commission relating to a new At-The-Market program.

BELLUS Health Inc. has announced the meeting and record dates for the special meeting of shareholders to be held in connection with the acquisition of the Company by GSK plc for US$2.0 billion pursuant to a plan of arrangement.

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers released its audited annual consolidated 2022 financial statements.

Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally.

Dizal announced that multiple clinical data of its two leading assets – sunvozertinib and golidocitinib have been selected for presentations at the 2023 ASCO, June 2-6, 2023 in Chicago.

Scott Arnold, executive vice president and chief information officer of Tampa General Hospital, has been named a top health care information technology leader by Becker’s Hospital Review on its 2023 “CIOs to Know” list.

Baudax Bio, Inc. announced the pricing of its public offering of an aggregate of 3,478,262 shares of its common stock, together with accompanying common stock purchase warrants, at a public offering price of $1.15 per share and accompanying warrants.